SCHEMBL20600830

SCHEMBL20600830

Nc1nc(Cl)c(-c2ccccc2)nc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.59
PKM P14618 2/20 0.59
ALDH1A1 P00352 4/20 0.55
LMNA P02545 3/20 0.55
GLA P06280 3/20 0.55
HPGD P15428 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MEN1 O00255 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
CSNK1A1 P48729 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
ADORA2A P29274 4/20 0.44
ADORA1 P30542 3/20 0.44
XDH P47989 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
DPP4 P27487 2/20 0.42
GAA P10253 3/20 0.42
ADORA2B P29275 1/20 0.42
DHFR P00374 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19810277 0.88 KDM4E (0.59) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL27316158 0.87 KDM4E (0.74) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL19831814 0.82 KDM4E (0.53) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL23430737 0.82 KDM4E (0.68) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL30838817 0.82 KDM4E (0.68) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL10444909 0.80 KDM4E (0.71) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL3864268 0.78 PLAU (0.54) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL5211515 0.77 KDM4E (0.60) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL29446663 0.75 KDM4E (0.68) KDM4EPKMALDH1A1LMNAGLA
SCHEMBL23542906 0.75 KDM4E (0.68) KDM4EPKMALDH1A1LMNAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
CN-110809577-A Modulators of adenosine A2A receptor 雷沃医疗有限公司 2020-02-18 CN disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 KDM4E 4607/4885PKM 1705/4885ALDH1A1 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.